Press Release

January 4, 2019

Generation Bio to Present at 37th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., january 4, 2019

Generation Bio, a company developing the first genetic medicines that can be re-dosed and titrated to effect for a lifetime of benefit, today announced the company will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 8, 2019.

President and Chief Executive Officer Geoff McDonough, M.D. will provide an overview of the company and anticipated milestones for 2019.

PRESENTATION DETAILS

Date: Tuesday, January 8, 2019
Time: 8:30 a.m. PT
Location: Westin St. Francis Hotel, Elizabethan C

 

About Generation Bio

Generation Bio is a biotechnology company developing a breakthrough class of genetic medicines to enable a new generation of people to live unaffected by inherited disease. The company is using its proprietary ceDNA platform to create gene therapies with drug-like properties – delivering durable gene expression with the ability to re-dose for individual patient titration and for the potential to sustain effect over a lifetime. Generation Bio was founded and launched by Atlas Venture and is headquartered in Cambridge, Mass. For more information, please visit www.generationbio.com or follow @generationbio.

Investors
Stern Investor Relations
(212) 362-1200
generationbio@sternir.com

Media
Marissa Picerno
Ten Bridge Communications
marissa@tenbridgecommunications.com
518-817-2176

Take a seat at the table.

We are always looking for those who are ready to share their vision, talent, and tenacity—who believe in our mission and themselves.

Imagine a world without genetic disease.

What do you see? More health? Fewer doctor appointments? More bike riding? More peanut butter and jelly sandwiches? More life?
See our shared vision.
cross